Rx-To-OTC Switch Consumer Costs Study 'Flawed' - CHPA
This article was originally published in The Tan Sheet
Executive Summary
A new study finding Rx-to-OTC switches increase out-of-pocket consumer expenses represents a "flawed fundamental analysis" of drug pricing data and ignores the indirect benefits of OTCs and added costs consumers bear for insurance coverage of prescriptions, the Consumer Healthcare Products Association maintains.
You may also be interested in...
Rx Antihistamine Switch Consumer Cost Increases Unlikely, Insurer Tells FDA
Switching Rx low- and non-sedating, second-generation antihistamines over-the-counter is unlikely to increase out-of-pocket costs for U.S. consumers based upon OTC pricing of the drugs in foreign countries, a health insurance rep told FDA June 29.
Rx Antihistamine Switch Consumer Cost Increases Unlikely, Insurer Tells FDA
Switching Rx low- and non-sedating, second-generation antihistamines over-the-counter is unlikely to increase out-of-pocket costs for U.S. consumers based upon OTC pricing of the drugs in foreign countries, a health insurance rep told FDA June 29.
Rx Antihistamine Switch Consumer Cost Increases Unlikely, Insurer Tells FDA
Switching Rx low- and non-sedating, second-generation antihistamines over-the-counter is unlikely to increase out-of-pocket costs for U.S. consumers based upon OTC pricing of the drugs in foreign countries, a health insurance rep told FDA June 29.